Loading…
Employees: 45
Size X4 Pharmaceuticals (XFOR) is a United States Health Care company (Biotechnology) with a market value of $315M, the 3070th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.18 on 6 Nov 2026.
Performance Over six months the shares fell 28.2%, against -22.3% for the median peer and -1.1% for the United States market (cap-weighted) — 8th lowest of 18 in its peer set.
Growth Revenue fell 51.6% over the last twelve months (peer median +7.4%); the operating margin is -554.7% (peer median -173.2%).
Valuation It trades at 11.6× enterprise value to sales against a peer median of 9.9× (7th most expensive of 14).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $15.8M | $35.1M | $2.56M | $0 | $0 |
| Revenue growth | — | +1,273% | — | — | — |
| Gross profit | $12.8M | $28.9M | $1.46M | -$2.00M | -$1.99M |
| EBITDA | -$86.2M | -$85.6M | -$141M | -$106M | -$86.1M |
| Net income | -$90.1M | -$79.2M | -$37.5M | -$101M | -$93.9M |
| Free cash flow | n/a | -$85.6M | -$131M | -$96.6M | -$77.2M |
| Capital expenditure | $5.00M | $3.00M | $7.33M | $60,000 | $103,000 |
| Total debt | $77.2M | $77.3M | $78.1M | $58.3M | $38.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | XFOR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.0% | -13.5% | 2nd highest of 20 |
| 6-month return | -28.2% | -22.3% | 8th lowest of 18 |
| Distance from 52-week high | -34.2% | -53.3% | 5th highest of 20 |
| Revenue growth (TTM) | -51.6% | +7.4% | 5th lowest of 14 |
| Operating margin | -554.7% | -173.2% | 7th lowest of 14 |
| EV / Sales | 11.6× | 9.9× | 7th most expensive of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals XFOR | United States | $315M | -28% | -52% | -555% | 11.6× | n/a | n/a |
| Galectin Therapeutics GALT | United States | $317M | +50% | n/a | n/a | n/a | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $310M | -39% | +7% | 7% | 2.0× | 6.0% | +11.9% |
| Agenus AGEN | United States | $323M | +87% | +30% | 27% | 4.4× | n/a | n/a |
| TransThera Sciences (Nanjing) 2617.HK | Hong Kong | $323M | -83% | n/a | -751% | 36.4× | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $325M | n/a | +395% | -173% | 9.9× | n/a | n/a |
| Century Therapeutics IPSC | United States | $304M | -27% | -100% | n/a | n/a | n/a | n/a |
| Circio CRNA.OL | Norway | $303M | -14% | n/a | n/a | n/a | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $328M | -57% | n/a | -57% | 4.8× | n/a | n/a |
| Kyverna Therapeutics KYTX | United States | $302M | -48% | n/a | n/a | n/a | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $330M | -32% | -100% | n/a | n/a | n/a | n/a |
| HJ Science 6132.HK | Hong Kong | $300M | n/a | +621% | -967% | 65.6× | n/a | n/a |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | 14.4× | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | 392.1× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 5.1× | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | 1,556.3× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 1.2× | 5.6% | +19.1% |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 2.7× | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | 22.8× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |